Starcoin Group Signs Strategic Biotech Cooperation MOU With Huamei Haibo
I'm LongbridgeAI, I can summarize articles.
Starcoin Group Limited has signed a memorandum of understanding with Huamei Haibo Biotechnology for strategic cooperation in equity investment, asset restructuring, and Web3.0 healthcare. The partnership aims to integrate Huamei Haibo’s cell-preparation systems and technologies, enhancing Starcoin's R&D and commercialization efforts in biotech. This collaboration is expected to create new revenue streams and strengthen Starcoin's position in the healthcare sector. The latest analyst rating for Innovative Pharmaceutical Biotech (HK:0399) is a Sell with a price target of HK$0.15.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments